[Using terasosine (setegis) in the treatment of hyperactive urinary bladder in elderly women].
Terasosine study covered 36 females aged 61 to 76 years (mean age 70.1 +/- 0.5 years) with hyperactive urinary bladder (HAUB). Thirty patients received alpha1-adrenoblocker terasosine (setegis) in a dose 1 mg twice a day for 2 months, 6 females were given placebo. At baseline, in 1 and 2 months the patients self-estimated urination, urine incontinence, imperative voiding, quality of life, discomfort, treatment satisfaction. Two months of therapy reduced imperative voiding by 70%, number of episodes of ugent incontinence by 90%. Capacity of the bladder increased by 30%. The patients reported improved condition of their bladder, 3 times lower discomfort because of imperative symptoms, satisfaction with treatment reached 71%. Patients of the placebo group noticed no significant positive trend in the above parameters. 43% patients with maximal improvement and cure of urine incontinence had good long-term results.
Gomberg
V G
VG
Nad'
Iu T
IuT
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects*; D014563:Urodynamics / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin